ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pimasertib

Also written as “Pimasertib”, “MSC1936369B” and “Pimasertib Capsule (Part A)”.

Its studies are mostly in Neoplasms · Melanoma · Neoplasm Metastasis · Ovarian Neoplasms · Carcinoma, Hepatocellular, led by 3 companies.

Drug pagePimasertib: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Aug 11, 200913 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany110 open or runningphase 2since Aug 11, 2009Aug 11, 2009none ahead
Day One Biopharmaceuticalsits history only10 open or runningphase 1since Jul 3, 2025Jul 3, 2025none ahead
Sanofiits history only10 open or runningphase 1since May 16, 2011May 16, 2011none ahead

Also a collaborator on its studies: Merck Serono S.A., Geneva and Merck Serono Co., Ltd., Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2009First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT00957580 · 81 enrolled · United States, France
  2. Sep 22, 2009Phase 1 study in NeoplasmsNCT00982865 · 182 enrolled · Australia, Belgium, France and more
  3. Nov 18, 2009Phase 2 study in NeoplasmsNCT01016483 · 141 enrolled · United States, Germany
  4. Mar 4, 2010Phase 2 study in Colorectal NeoplasmsNCT01085331 · 16 enrolled · Belgium, Italy, Spain
  5. Apr 18, 2011Phase 1 study in Neoplasm MetastasisNCT01390818 · 146 enrolled · United States, Italy, Spain
  6. Jun 20, 2011Phase 1 study in NeoplasmsNCT01378377 · 33 enrolled · United States
  7. Aug 15, 2012Phase 1 study in Carcinoma, HepatocellularNCT01668017 · 26 enrolled · Japan
  8. Sep 13, 2012Phase 1 study in NeoplasmsNCT01713036 · 6 enrolled · Hungary
  9. Sep 14, 2012Phase 2 study in MelanomaNCT01693068 · 194 enrolled · United States, Australia, Belgium and more
  10. Aug 23, 2013Phase 2 study in Ovarian NeoplasmsNCT01936363 · 65 enrolled · United States, Australia, Belgium and more
  11. Nov 8, 2013Phase 1 study in NeoplasmsNCT01992874 · 38 enrolled · United States

TargetBeta

“An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) ”NCIt, by rule
“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cobimetinibruleHoffmann-La Rochephase 338
mirdametinibruleMerck KGaA, Darmstadt, Germanyphase 29
polfurmetinibPfizerphase 13

Studies

All 11 Merck KGaA, Darmstadt, Germany leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01992874Neoplasms · United States1CompletedMay 31, 201438
NCT01936363Ovarian Neoplasms · United States, Australia, Belgium and more2CompletedMay 31, 201565
NCT01693068Melanoma · United States, Australia, Belgium and more2CompletedJul 4, 2015194
NCT01713036Neoplasms · Hungary1CompletedJul 31, 20146
NCT01668017Carcinoma, Hepatocellular · Japan1TerminatedMay 31, 201526
NCT01378377Neoplasms · United States1TerminatedFeb 23, 201233
NCT01390818Neoplasm Metastasis · United States, Italy, Spain1CompletedApr 2015146
NCT01085331Colorectal Neoplasms · Belgium, Italy, Spain2TerminatedApr 201216
NCT01016483Neoplasms · United States, Germany2CompletedDec 31, 2013141
NCT00982865Neoplasms · Australia, Belgium, France and more1CompletedMar 31, 2013182
NCT00957580Leukemia, Myeloid, Acute · United States, France2TerminatedDec 31, 201281

How it is read

Names in the registry

  • “Pimasertib”, 16 entries
  • “MSC1936369B”, 5 entries
  • “Pimasertib Capsule (Part A)”, 2 entries
  • “Pimasertib Tablet (Part A)”, 2 entries
  • “MSC1936369B (pimasertib)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.